Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
-
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica))
;
Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ;
Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ;
Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ;
Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ;
Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ;
Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ;
Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ;
Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ;
Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ;
Universitat Autònoma de Barcelona